IGF2BP1 and neoplasm: These include inhibition of chymotrypsin-like activity of the proteasome, involved in proteasomal regulation of cancer signaling pathways [27,38]; rise of intracellular labile zinc, which has second messenger molecule activities in tumor cells [34]; and modulation of microRNAs expression, highly involved in cancer development and chemoresistance [63], leading to inhibition of the oncogenic RNA-binding proteins insulin-like growth factor-2 binding protein 1 and 3 (IGF2BP1 and IGF2BP3) through the upregulation of miR-1275 [29].